Excitotoxic neuronal death and the pathogenesis of Huntington's disease.

[1]  M. Hayden,et al.  Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington’s disease , 2007, Neuroscience.

[2]  J. Epplen,et al.  NR2A and NR2B receptor gene variations modify age at onset in Huntington disease in a sex-specific manner , 2007, Human Genetics.

[3]  L. Massieu,et al.  Exacerbation of excitotoxic neuronal death induced during mitochondrial inhibition in vivo: Relation to energy imbalance or ATP depletion? , 2007, Neuroscience.

[4]  L. Raymond,et al.  Altered NMDA Receptor Trafficking in a Yeast Artificial Chromosome Transgenic Mouse Model of Huntington's Disease , 2007, The Journal of Neuroscience.

[5]  L. Raymond,et al.  N-Methyl-d-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease , 2007, Progress in Neurobiology.

[6]  Carlos Cepeda,et al.  The corticostriatal pathway in Huntington's disease , 2007, Progress in Neurobiology.

[7]  A. Camacho,et al.  Sustained metabolic inhibition induces an increase in the content and phosphorylation of the NR2B subunit of N-methyl-d-aspartate receptors and a decrease in glutamate transport in the rat hippocampus in vivo , 2007, Neuroscience.

[8]  T. Videen,et al.  Selective defect of in vivo glycolysis in early Huntington's disease striatum , 2007, Proceedings of the National Academy of Sciences.

[9]  J. Ryu,et al.  Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington’s disease , 2006, Neuroscience.

[10]  L. Massieu,et al.  d-β-Hydroxybutyrate Prevents Glutamate-Mediated Lipoperoxidation and Neuronal Damage Elicited during Glycolysis Inhibition In Vivo , 2006, Neurochemical Research.

[11]  M. Beal,et al.  PGC-1α, a New Therapeutic Target in Huntington's Disease? , 2006, Cell.

[12]  S. Luquet,et al.  Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. , 2006, Cell metabolism.

[13]  Jiandie D. Lin,et al.  Suppression of Reactive Oxygen Species and Neurodegeneration by the PGC-1 Transcriptional Coactivators , 2006, Cell.

[14]  Dimitri Krainc,et al.  Transcriptional Repression of PGC-1α by Mutant Huntingtin Leads to Mitochondrial Dysfunction and Neurodegeneration , 2006, Cell.

[15]  A. Spada,et al.  Bergmann glia expression of polyglutamine-expanded ataxin-7 produces neurodegeneration by impairing glutamate transport , 2006, Nature Neuroscience.

[16]  M. Levine,et al.  Changes in Expression of N-Methyl-D-Aspartate Receptor Subunits Occur Early in the R6/2 Mouse Model of Huntington’s Disease , 2006, Developmental Neuroscience.

[17]  R. Ferrante,et al.  Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. , 2006, Biochimica et biophysica acta.

[18]  R. Schwarcz,et al.  Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease , 2006, Experimental Neurology.

[19]  Ji-Yeon Shin,et al.  Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity , 2005, The Journal of cell biology.

[20]  Elena Cattaneo,et al.  Normal huntingtin function: an alternative approach to Huntington's disease , 2005, Nature Reviews Neuroscience.

[21]  C. Cepeda,et al.  Alterations in N‐methyl‐D‐aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease , 2005, Journal of neuroscience research.

[22]  G. Johnson,et al.  Mitochondrial Respiration and ATP Production Are Significantly Impaired in Striatal Cells Expressing Mutant Huntingtin* , 2005, Journal of Biological Chemistry.

[23]  Hervé Chneiweiss,et al.  Expanded polyglutamine peptides disrupt EGF receptor signaling and glutamate transporter expression in Drosophila. , 2005, Human molecular genetics.

[24]  R. Llinás,et al.  Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Epplen,et al.  NR2A and NR2B receptor gene variations modify age at onset in Huntington disease , 2005, Neurogenetics.

[26]  S. Augood,et al.  Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease , 2004, Neurobiology of Disease.

[27]  F. Pedata,et al.  Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow , 2004, Neurobiology of Disease.

[28]  I. Bezprozvanny,et al.  HAP1 facilitates effects of mutant huntingtin on inositol 1,4,5‐trisphosphate‐induced Ca2+ release in primary culture of striatal medium spiny neurons , 2004, The European journal of neuroscience.

[29]  J. Schiefer,et al.  The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease , 2004, Brain Research.

[30]  M. MacDonald,et al.  Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. , 2004, Human molecular genetics.

[31]  M. Beal,et al.  The Energetics of Huntington's Disease , 2004, Neurochemical Research.

[32]  L. Raymond,et al.  Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease , 2004, Molecular and Cellular Neuroscience.

[33]  R. Scarpulla,et al.  Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. , 2004, Genes & development.

[34]  L. Raymond,et al.  Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease , 2003, Neurobiology of Aging.

[35]  Ruth Luthi-Carter,et al.  Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation , 2003, Neurobiology of Disease.

[36]  S. Swinnen,et al.  Creatine supplementation in Huntington’s disease , 2003, Neurology.

[37]  M. MacDonald,et al.  Neocortical neurons cultured from mice with expanded cag repeats in the huntingtin gene: unaltered vulnerability to excitotoxins and other insults , 2003, Neuroscience.

[38]  C. Parsons,et al.  Expression of Polyglutamine-expanded Huntingtin Induces Tyrosine Phosphorylation of N-Methyl-D-aspartate Receptors* , 2003, Journal of Biological Chemistry.

[39]  He Li,et al.  Mutant Huntingtin Causes Context-Dependent Neurodegeneration in Mice with Huntington's Disease , 2003, The Journal of Neuroscience.

[40]  M. MacDonald,et al.  Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. , 2003, Human molecular genetics.

[41]  U. Bonuccelli,et al.  Amantadine in Huntington's disease: open-label video-blinded study , 2002, Neurological Sciences.

[42]  K. Lindenberg,et al.  Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. , 2002, Brain : a journal of neurology.

[43]  James R. Burke,et al.  Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines , 2002, Nature Neuroscience.

[44]  C. Arias,et al.  β-Amyloid Neurotoxicity Is Exacerbated during Glycolysis Inhibition and Mitochondrial Impairment in the Rat Hippocampus in Vivo and in Isolated Nerve Terminals: Implications for Alzheimer's Disease , 2002, Experimental Neurology.

[45]  L. Raymond,et al.  Increased Sensitivity to N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity in a Mouse Model of Huntington's Disease , 2002, Neuron.

[46]  Ole A. Andreassen,et al.  Therapeutic Effects of Coenzyme Q10 and Remacemide in Transgenic Mouse Models of Huntington's Disease , 2002, The Journal of Neuroscience.

[47]  H. Robertson,et al.  Immediate‐early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice , 2002, Journal of neuroscience research.

[48]  C. Cepeda,et al.  NMDA receptor function in mouse models of Huntington disease , 2001, Journal of neuroscience research.

[49]  A. Mahal,et al.  Impaired Glutamate Uptake in the R6 Huntington's Disease Transgenic Mice , 2001, Neurobiology of Disease.

[50]  P. Reddy,et al.  Polyglutamine-expanded Huntingtin Promotes Sensitization of N-Methyl-d-aspartate Receptors via Post-synaptic Density 95* , 2001, The Journal of Biological Chemistry.

[51]  O. Andreassen,et al.  Creatine Increases Survival and Delays Motor Symptoms in a Transgenic Animal Model of Huntington's Disease , 2001, Neurobiology of Disease.

[52]  Mark Farrant,et al.  NMDA receptor subunits: diversity, development and disease , 2001, Current Opinion in Neurobiology.

[53]  L. Massieu,et al.  Strategies for neuroprotection against L‐trans‐2,4‐pyrrolidine dicarboxylate‐induced neuronal damage during energy impairment in vitro , 2001, Journal of neuroscience research.

[54]  J. Penney,et al.  The Role of Group I and Group II Metabotropic Glutamate Receptors in Modulation of Striatal NMDA and Quinolinic Acid Toxicity , 2001, Experimental Neurology.

[55]  Michael R. Hayden,et al.  Mutant Huntingtin Enhances Excitotoxic Cell Death , 2001, Molecular and Cellular Neuroscience.

[56]  O. Hansson,et al.  Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice , 2001, The European journal of neuroscience.

[57]  G. Battaglia,et al.  Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective , 2000, Neuropharmacology.

[58]  N. Gomez-roman,et al.  In Vivo Potentiation of Glutamate-Mediated Neuronal Damage after Chronic Administration of the Glycolysis Inhibitor Iodoacetate , 2000, Experimental Neurology.

[59]  A. Morton,et al.  Mice transgenic for the human Huntington’s disease mutation have reduced sensitivity to kainic acid toxicity , 2000, Brain Research Bulletin.

[60]  J. Brotchie,et al.  NMDA receptors in the basal ganglia , 2000, Journal of anatomy.

[61]  R. Schwarcz,et al.  Early kynurenergic impairment in Huntington's Disease and in a transgenic animal model , 2000, Neuroscience Letters.

[62]  M. MacDonald,et al.  Evidence for the GluR6 gene associated with younger onset age of Huntington’s disease , 1999, Neurology.

[63]  L. Raymond,et al.  Influence of lamotrigine on progression of early Huntington disease , 1999, Neurology.

[64]  O. Hansson,et al.  Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[65]  L. Raymond,et al.  Subtype‐Specific Enhancement of NMDA Receptor Currents by Mutant Huntingtin , 1999, Journal of neurochemistry.

[66]  Claire-Anne Gutekunst,et al.  A YAC Mouse Model for Huntington’s Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxicity, and Selective Striatal Neurodegeneration , 1999, Neuron.

[67]  S. Tabrizi,et al.  Biochemical abnormalities and excitotoxicity in Huntington's disease brain , 1999, Annals of neurology.

[68]  L. Massieu,et al.  Transient Inhibition of Glutamate Uptake In Vivo Induces Neurodegeneration when Energy Metabolism Is Impaired , 1999, Journal of neurochemistry.

[69]  Í. Lopes-Cendes,et al.  Brain glyceraldehyde-3-phosphate dehydrogenase activity in human trinucleotide repeat disorders. , 1998, Archives of neurology.

[70]  W. Strittmatter,et al.  Glyceraldehyde 3-Phosphate Dehydrogenase Abnormality in Metabolically Stressed Huntington Disease Fibroblasts , 1998, Developmental Neuroscience.

[71]  C. Garner,et al.  SAP90 Binds and Clusters Kainate Receptors Causing Incomplete Desensitization , 1998, Neuron.

[72]  S. W. Davies,et al.  Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[73]  B R Rosen,et al.  1H NMR spectroscopy studies of Huntington's disease , 1998, Neurology.

[74]  R. Gross,et al.  3-Nitropropionic acid exacerbates N-methyl-d-aspartate toxicity in striatal culture by multiple mechanisms , 1998, Neuroscience.

[75]  S. W. Davies,et al.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.

[76]  N L Foster,et al.  Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease , 1997, Neurology.

[77]  M. Beal,et al.  Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia , 1997, Annals of neurology.

[78]  G Norbury,et al.  Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[79]  A Weindl,et al.  Changes of NMDA Receptor Subunit (NR1, NR2B) and Glutamate Transporter (GLT1) mRNA Expression in Huntington's Disease—An In Situ Hybridization Study , 1997, Journal of neuropathology and experimental neurology.

[80]  J Deas,et al.  Ion homeostasis in brain cells: differences in intracellular ion responses to energy limitation between cultured neurons and glial cells , 1997, Neuroscience.

[81]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[82]  M. Mcdermott,et al.  A controlled trial of remacemide hydrochloride in Huntington's disease , 1996, Movement disorders : official journal of the Movement Disorder Society.

[83]  M. Beal,et al.  Chronic 3-Nitropropionic Acid Treatment in Baboons Replicates the Cognitive and Motor Deficits of Huntington’s Disease , 1996, The Journal of Neuroscience.

[84]  A. Roses,et al.  Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH , 1996, Nature Medicine.

[85]  B. Hyman,et al.  Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[86]  J. Bockaert,et al.  NMDA-dependent superoxide production and neurotoxicity , 1993, Nature.

[87]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[88]  Bert Sakmann,et al.  Heteromeric NMDA Receptors: Molecular and Functional Distinction of Subtypes , 1992, Science.

[89]  H. Herzog,et al.  Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. , 1990, Brain : a journal of neurology.

[90]  J. Penney,et al.  Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. , 1990, The New England journal of medicine.

[91]  J. Penney,et al.  NMDA receptor losses in putamen from patients with Huntington's disease. , 1988, Science.

[92]  A. Novelli,et al.  Glutamate becomes neurotoxic via the N-methyl-d-aspartate receptor when intracellular energy levels are reduced , 1988, Brain Research.

[93]  R. Schwarcz,et al.  3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[94]  G. Reynolds,et al.  Reduced high-affinity glutamate uptake sites in the brains of patients with Huntington's disease , 1986, Neuroscience Letters.

[95]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[96]  G. Graveland,et al.  Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. , 1985, Science.

[97]  G. Reynolds,et al.  Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and γ-glutamyl transpeptidase in post-mortem brain from Huntington's disease and agonal cases , 1985, Journal of the Neurological Sciences.

[98]  R. Schwarcz,et al.  II: Excitotoxic models for neurodegenerative disorders , 1984 .

[99]  A. Young,et al.  A polymorphic DNA marker genetically linked to Huntington's disease , 1983, Nature.

[100]  C. Markham,et al.  Cerebral metabolism and atrophy in huntington's disease determined by 18FDG and computed tomographic scan , 1982, Annals of neurology.

[101]  H. Goebel,et al.  Juvenile Huntington chorea , 1978, Neurology.

[102]  J. Coyle,et al.  Neurochemical sequelae of kainate injections in corpus striatum and substantia nigra of the rat. , 1977, Life sciences.

[103]  P. Mcgeer,et al.  Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids , 1976, Nature.

[104]  S. Dunnett,et al.  Pharmaceutical, cellular and genetic therapies for Huntington's disease. , 2006, Clinical science.

[105]  M. Gerlach,et al.  The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease. , 2004, Journal of neural transmission. Supplementum.

[106]  D. Choi,et al.  Hypoxic-Ischemic Brain Injury and Oxidative Stress , 1999 .

[107]  I. R. López,et al.  Enfermedad de Huntington , 1998 .

[108]  R. Durbin,et al.  Structure and expression of the Huntington's disease gene: Evidence against simple inactivation due to an expanded CAG repeat , 1994, Somatic cell and molecular genetics.

[109]  Peter S. Harper,et al.  Huntington's disease , 1991 .

[110]  P. Molinoff,et al.  Basic Neurochemistry: Molecular, Cellular and Medical Aspects , 1989 .